Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBCBS Rhode Island WES/WGS Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage, medical-necessity criteria, and authorization requirements for whole exome sequencing, whole genome sequencing, and rapid sequencing for unexplained genetic disorders in Medicare Advantage and commercial products.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyWhole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewMay 20, 2026
    Next Review DateN/A
    Key ActionThe ordering physician must obtain prior authorization for Medicare Advantage Plans and handle authorization and appeals personally.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered test codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    25%-60%WES diagnostic yield
    31% vs 3%Rapid WGS diagnosis by 28 days
    30%-60%Rapid sequencing yield
    RequiredMedicare Advantage authorization

    Medical Necessity and Coverage Criteria

    Standard WES for unexplained congenital or neurodevelopmental disorders

    Standard WES, with trio testing when possible, may be considered medically necessary when ALL of the following are met.

    Standard WES criteria

    • Clinical genetics evaluation: The individual has been evaluated by a clinician with expertise in clinical genetics, including at minimum a family history and phenotype description, and has been counseled about the potential risks of genetic testing.
    • Potential clinical benefit: There is potential for a change in management and clinical outcome for the individual being tested.
    • Unresolved suspected genetic etiology: A genetic etiology is considered the most likely explanation for the phenotype despite previous genetic testing, such as chromosomal microarray analysis and/or targeted single-gene testing, OR previous genetic testing failed to yield a diagnosis and the affected individual faces invasive procedures or testing as the next diagnostic step, such as muscle biopsy.

    Rapid WES or WGS for critically ill infants

    Rapid WES or rapid WGS, with trio testing when possible, may be considered medically necessary when BOTH of the following groups are satisfied.

    Rapid sequencing criteria

    • At least one qualifying clinical feature

      • Multiple congenital anomalies: The infant has multiple congenital anomalies.
      • Genetic or metabolic indicators: An abnormal laboratory test or clinical features suggest a genetic disease or complex metabolic phenotype.
      • Abnormal response to therapy: There is an abnormal response to standard therapy for a major underlying condition.
    • No listed intensive-care exclusion

    Trio testing implementation

    Trio testing is preferred whenever possible but should not delay indicated rapid testing.

    Family comparator testing: When possible, test the child and both parents. If both parents are not immediately available, test one available parent and test one or both parents later if needed.

    Rapid WGS or WES for critically ill infants

    Rapid WGS or rapid WES is medically necessary when the applicable medical criteria are met.

    Rapid sequencing in critically ill infants: The individual is a critically ill infant or child with a suspected genetic disorder of unknown etiology following a standard diagnostic workup and receives rapid whole genome sequencing or rapid whole exome sequencing; trio testing is performed when possible.

    Evidence supports improved diagnostic yield and clinically meaningful management changes. In reported studies, diagnostic yield was 30% to 60%; one randomized trial reported genetic diagnosis within 28 days in 31% with rapid WGS versus 3% with standard testing, and the NICUSeq trial reported diagnostic yield of 31.0% versus 15.0% with delayed reporting.

    For Medicare Advantage Plans, WES used to diagnose genetic disorders in situations other than the policy’s qualifying indications is not covered. For Commercial Products, such use is not medically necessary.

    Repeat WES, including re-analysis of previous test results, is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products.

    WES used for screening for genetic disorders is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products.

    For Commercial Products, WES is not medically necessary when used for indications other than the policy’s qualifying diagnostic uses, including repeat testing, re-analysis of prior results, or genetic screening. The evidence is insufficient to establish improvement in net health outcomes for these uses.

    Covered Clinical Indications

    Unexplained congenital or neurodevelopmental disorders after standard workup

    Standard WES, with trio testing when possible, may be medically necessary for an unexplained congenital or neurodevelopmental disorder after standard workup when ALL of the following are met.

    Covered standard WES indication

    • Clinical genetics evaluation: The individual has been evaluated by a clinician with expertise in clinical genetics, including a family history and phenotype description, and has been counseled about the potential risks of genetic testing.
    • Potential clinical benefit: There is potential for a change in management and clinical outcome for the individual being tested.
    • Unresolved suspected genetic etiology: A genetic etiology remains the most likely explanation for the phenotype despite prior genetic testing, such as chromosomal microarray analysis and/or targeted single-gene testing, OR prior genetic testing failed to establish a diagnosis and invasive procedures or testing would otherwise be the next diagnostic step, such as muscle biopsy.

    Eligibility Requirements

    A family history must be documented as part of the clinical genetics evaluation. The evaluation should also include a phenotype description and be performed by a clinician with expertise in clinical genetics.

    For standard WES, prior genetic testing such as chromosomal microarray analysis and/or targeted single-gene testing should have been performed. If prior testing did not establish a diagnosis, documentation must explain why a genetic etiology remains most likely or why invasive diagnostic procedures or testing would otherwise be the next step.

    Coding and Covered Test Codes

    Addressed and potentially medically necessary testsCPTCovered
    0214UGenomic Unity® Exome Plus Analysis -Proband (Variantyx, Inc.)
    0215UGenomic Unity® Exome Plus Analysis -Comparator (Variantyx, Inc.)
    Medically Necessary CPT CodesCPTCovered
    0214URare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband
    0215URare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)

    Provider Requirements and Administrative Actions

    Prior Authorization

    Authorization by Ordering Physician

    Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products for Genomic Unity® Exome Plus Analysis—Proband (CPT 0214U) and Comparator (CPT 0215U). The ordering physician is responsible for the authorization, appeal, and related administrative processes.

    • Genomic Unity® Exome Plus Analysis—Proband: CPT 0214U
    • Genomic Unity® Exome Plus Analysis—Comparator: CPT 0215U
    • Medicare Advantage: prior authorization required
    • Commercial Products: prior authorization recommended
    Documentation Required

    Clinical Genetics Evaluation and Counseling

    Document that the individual has been evaluated by a clinician with expertise in clinical genetics and has received counseling about the potential risks of genetic testing.

    Clinical and Technical Background

    Whole exome sequencing (WES) primarily sequences protein-coding regions of the genome, whereas whole genome sequencing (WGS) sequences both coding and noncoding regions. These tests may help diagnose suspected genetic disorders that remain unexplained after a standard clinical workup and may inform management, follow-up, morbidity reduction, and reproductive planning. Trio testing of the child and both parents is preferred when possible because it may improve diagnostic yield and reduce false-positive findings.

    Definitions

    Whole exome sequencing (WES)
    DefinitionWhole exome sequencing (WES) is targeted next-generation sequencing of the portion of the genome containing protein-coding DNA.
    Genomic scopeWES generally represents approximately 1% of the genome.
    UseWES may be used when disorders or anomalies are not explained by a standard clinical workup.
    Whole genome sequencing (WGS)
    DefinitionWhole genome sequencing (WGS) uses next-generation sequencing techniques to sequence the genome.
    Genomic scopeWGS sequences both coding and noncoding regions of the genome.
    Use

    Noncovered and Nonqualifying Uses

    The following uses are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products: WES for diagnosis of genetic disorders in situations other than the policy’s qualifying diagnostic indications; repeat WES, including re-analysis of previous test results; and WES for genetic screening.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyWhole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewMay 20, 2026
    Next Review DateN/A
    Key ActionThe ordering physician must obtain prior authorization for Medicare Advantage Plans and handle authorization and appeals personally.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered Clinical IndicationsEligibility RequirementsCoding and Covered Test CodesProvider Requirements and Administrative ActionsClinical and Technical BackgroundDefinitionsNoncovered and Nonqualifying Uses
  1. Excluded intensive-care admission reason: None of these exclusions applies: infection with normal response to therapy; isolated prematurity; isolated unconjugated hyperbilirubinemia; hypoxic ischemic encephalopathy; a confirmed genetic diagnosis that explains the illness; isolated transient neonatal tachypnea; or a nonviable neonate.
  2. Critically ill infants in neonatal or pediatric intensive care with suspected genetic disorder of unknown etiology

    Rapid WES or rapid WGS, with trio testing when possible, may be medically necessary for a critically ill infant in neonatal or pediatric intensive care when BOTH groups of criteria are met.

    Covered rapid sequencing indication

    • Qualifying clinical presentation

      • Multiple congenital anomalies: The infant has multiple congenital anomalies.
      • Genetic or metabolic indicators: An abnormal laboratory test or clinical features suggest a genetic disease or complex metabolic phenotype.
      • Abnormal response to therapy: There is an abnormal response to standard therapy for a major underlying condition.
    • No listed intensive-care exclusion: None of the following applies regarding the reason for admission to intensive care: infection with normal response to therapy; isolated prematurity; isolated unconjugated hyperbilirubinemia; hypoxic ischemic encephalopathy; confirmed genetic diagnosis explaining the illness; isolated transient neonatal tachypnea; or nonviable neonate.

    Critically ill infants or children after standard diagnostic workup

    Rapid WGS or rapid WES may be medically necessary for a critically ill infant or child with a suspected genetic disorder of unknown etiology after a standard diagnostic workup. Trio testing is used when possible.

    Rapid sequencing after standard diagnostic workup

    • Trio testing: Testing of the child and both parents is performed when possible; testing should not be delayed when rapid testing is indicated.
    • Expected diagnostic and management value: The test is supported by evidence of improved diagnostic yield and clinically meaningful changes in management, including avoidance of invasive procedures, medication changes to reduce morbidity, discontinuation of or additional testing, initiation of palliative care, or reproductive planning.

      Studies of critically ill infants and children reported diagnostic yields of 30% to 60% for pathogenic or likely pathogenic variants. In one randomized trial, genetic diagnosis within 28 days occurred in 31% with rapid WGS versus 3% with standard testing; the NICUSeq trial reported diagnostic yield of 31.0% with rapid WGS versus 15.0% with delayed reporting and more frequent management changes.

    • Include a family history.
    • Provide a description of the individual’s phenotype.
    • Document counseling regarding the potential risks of genetic testing.
    Documentation Required

    Expected Management Impact

    Document the potential for the genetic test to change the individual’s management and clinical outcome.

    • Explain how the test results could affect clinical management.
    • Describe the expected impact on the individual’s clinical outcome.
    Documentation Required

    Prior Testing and Diagnostic Escalation

    Document the prior diagnostic evaluation and why whole exome sequencing is the appropriate next step. A genetic etiology must remain the most likely explanation despite prior testing, or prior testing must have been nondiagnostic and the individual must otherwise face an invasive next diagnostic procedure.

    • Identify prior testing, such as chromosomal microarray analysis and/or targeted single-gene testing.
    • Explain the rationale for escalation to whole exome sequencing.
    • If prior testing was nondiagnostic, document the impending invasive procedure or testing, such as a muscle biopsy.
    Documentation Required

    Rapid Testing Clinical Documentation

    For rapid whole exome or whole genome sequencing in a critically ill infant in neonatal or pediatric intensive care, document a suspected genetic disorder of unknown etiology and at least one qualifying clinical finding. Also document that the intensive-care admission is not attributable to an excluded circumstance.

    • Qualifying finding: multiple congenital anomalies.
    • Qualifying finding: abnormal laboratory test or clinical features suggesting a genetic disease or complex metabolic phenotype.
    • Qualifying finding: abnormal response to standard therapy for a major underlying condition.
    • The admission must not be for an infection with a normal response to therapy or isolated prematurity.
    Denial Risk

    Unauthorized Testing or Laboratory-Led Authorization

    Laboratories and other third parties may not obtain clinical authorization or participate in the ordering physician’s authorization or appeal process, including preparation of documentation of clinical appropriateness. Unauthorized laboratory services will be denied as the financial liability of the participating laboratory and may not be billed to the member.

    • A laboratory representative or other party with a relationship to the laboratory may not obtain authorization on behalf of the ordering physician.
    • Laboratory or third-party support of any portion of the authorization or appeal process violates the policy and may result in severe action, including termination from the BCBSRI provider network.
    • If authorization was not followed or clinical appropriateness was denied, the laboratory may not shift financial liability to the member.
    Denial Risk

    Excluded Indications

    The following indications are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products because evidence is insufficient to establish improved net health outcomes.

    • Whole exome sequencing for diagnosis of genetic disorders in all other situations.
    • Repeat whole exome sequencing, including re-analysis of previous test results.
    • Whole exome sequencing for screening for genetic disorders.
    Documentation Required

    Provider Actions: Genetic Counseling

    Before ordering testing, counsel the individual or family about the potential risks of genetic testing and document the evaluation by a clinician with expertise in clinical genetics.

    • Include family history and phenotype description in the clinical documentation.
    • Involve a qualified clinical genetics clinician in the evaluation and counseling.
    Prior Authorization

    Provider Actions: Authorization and Appeals

    The ordering physician must manage prior authorization, medical-necessity documentation, appeals, and related administrative processes. Laboratories and third parties cannot obtain authorization or prepare clinical-appropriateness documentation on the ordering physician’s behalf.

    • The ordering physician remains responsible for authorization and appeals for the applicable testing.
    • Do not use a laboratory representative or a third party with a laboratory relationship to facilitate any portion of authorization or a subsequent appeal.
    • Unauthorized laboratory services are denied as the participating laboratory’s financial liability and may not be billed to the member.
    WGS may be used when disorders or anomalies are not explained by a standard clinical workup.
    Trio testing
    Standard configurationTrio testing examines the child and both parents when possible.
    Availability exceptionIf both parents are not immediately available, test one available parent; one or both parents can be tested later if needed.
    Rapid testingTrio testing is preferred whenever possible but should not delay testing of a critically ill individual when rapid testing is indicated.